WuXi Vaccines was named "Best Vaccine CMO of the Year" for the second consecutive year at the 2023 Asia-Pacific Vaccine Excellence Awards (AVEA) ceremony.
The AVEA 2023 event was to recognize the remarkable accomplishments of vaccine and supply chain experts, organizations, and cutting-edge technologies in Asia, with ultimate award winners determined through voting by industry experts, professionals, and stakeholders in the vaccine community. WuXi Vaccines stood out among the nominees for its commitment to advancing global vaccine accessibility, especially in low and middle-income countries.
Notably, WuXi Vaccines has played a crucial role in the fight against COVID-19 by manufacturing of hundreds of millions doses of COVID-19 vaccine, enabling our client to supply the vaccine to over 180 countries. Recently, its first standalone vaccines CDMO site in Suzhou, China, has launched and successfully passed an on-site GMP audit by a global vaccine leader, which will accelerate global clients’ project timelines by providing high-quality end-to-end services for diversified vaccines. Its Dundalk facility in Ireland has reached significant milestones, including the initiation of Tech Transfer (TT), and has made substantial progress in commissioning qualification and validation (CQV) activities. The QC potency lab at the facility became operational in July 2020 and received the GMP certificate from the Ireland Health Products Regulatory Authority (HPRA) in July 2022.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!